pharmaphorum4d
EMA panel endorses AI for MASH clinical trials
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
Everyday Health13d
Consumer's Guide to THR-Beta Agonists for MASH
THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...
Investing14d
Madrigal Pharmaceuticals appoints new board member
The company’s medication, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently being evaluated in a Phase 3 trial for compensated ...
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...
Nasdaq14d
Madrigal Pharmaceuticals Announces Dr. Fred Craves' Retirement and Appointment of Dr. Jacqualyn Fouse to Board of Directors
and the early launch of Rezdiffra has demonstrated the compelling benefit that this innovative medicine represents for patients. I look forward to working with this team that has successfully ...
Mena FN14d
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Its Board Of Directors
and the early launch of Rezdiffra has demonstrated the compelling benefit that this innovative medicine represents for patients. I look forward to working with this team that has successfully ...
Investing14d
Madrigal Pharmaceuticals appoints new board member
The company’s medication, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently being evaluated in a Phase 3 trial for ...